Aim: Review mortality, infections and CSF sampling in EVD patients. Methods: Theatre shunt register and laboratory results were used to collect data from August 2012 to b2014. Results: 141 EVDs were inserted in 117 patients. The mortality rate within 2 months of operation was 36%. Mortality was highest in patients with intra-ventricular haemorrhage (69%) and malignant tumours (67%). 258 CSF samples were taken for analysis costing £4,987.14. 38% of patients had an intra-operative sample sent, none of which grew an infective organism without pre-existing shunt or infection. The iatrogenic infection rate was 7% however 4 of these were potential contaminant organisms (coagulasenegative staphylococcus), and a further 4 contaminants were not treated. Neither the number of samples taken from EVDs, nor the CSF cell counts were associated with infection. Conclusion: We have demonstrated the high mortality associated with patients requiring EVDs, knowledge of which has been incorporated into our practise when counselling patients and families. We have also highlighted the lack of value of cell count intra-operative sampling in predicting infection. To improve efficiency our microbiologists are reviewing use of routine cell counts, favouring culture only. We also recommend only sampling patients with a high index of suspected infection to avoid overtreating contaminants. Aim: Parathyroidectomy is the definitive cure for primary hyperparathyroidism. Re-operative parathyroidectomy is required when the first operation has been unsuccessful, however, re-operative surgery has a higher complication rate and a higher rate of failure to cure. Our study looked at our departmental experience of re-operative parathyroidectomy. Methods: Using an internal database we identified all patients who had undergone re-operative parathyroidectomy between 2006 and 2014. We reviewed results from the pre-operative work up, the operative note, and the post-operative biochemistry and histology for the initial and reoperative procedure.
Aim: Parathyroidectomy is the definitive cure for primary hyperparathyroidism. Re-operative parathyroidectomy is required when the first operation has been unsuccessful, however, re-operative surgery has a higher complication rate and a higher rate of failure to cure. Our study looked at our departmental experience of re-operative parathyroidectomy.
Methods: Using an internal database we identified all patients who had undergone re-operative parathyroidectomy between 2006 and 2014. We reviewed results from the pre-operative work up, the operative note, and the post-operative biochemistry and histology for the initial and reoperative procedure.
Results: During this time period over 700 parathyroidectomies were performed. Of these, we identified 46 re-operative patients for whom we had the relevant data to include them in the study. A large proportion of patients had negative, equivocal or discordant conventional imaging and therefore went on to have more invasive localisation studies. Most abnormal parathyroid glands were found in eutopic locations. Of the ectopic glands, the most common locations were: intra-thyroidal, intrathymic, and mediastinal. 10 patients were found to have multiple adenomas and 4 patients had supernumerary parathyroid glands. 28% of the patients had concurrent thyroid disease. Conclusion: This study has identified patterns of disease persistence and recurrence in patients who have undergone re-operative parathyroidectomy. (2 of 22) showed overexpression against the HER2 ECD epitope (3/3 with gene amplification). 50% (1 of 2) of overexpressing showed co-expression of EGFR and HER2. The coexpressed case showed significant disease progression. The pattern of distribution was heterogeneous in all EGFR cases but uniform in all of the HER2 cases. HER3 and HER4 overexpression was not seen in any cases.
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Conclusion:
This pilot study suggests a relationship between EGFR and HER2. Interestingly, HER3 and HER4 lacked correlatation with either of these in contrast to reported relationships. The prognostic utility EGFR and HER2 co-expression to predict an aggressive early gastric cancer phenotype warrants further investigation. 
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